Author:
Chen Juan,Liu Li,Ma Runzhi,Pang Aiming,Yang Donglin,Chen Xin,Wei Jialin,He Yi,Zhang Rongli,Zhai Weihua,Ma Qiaoling,Jiang Erlie,Han Mingzhe,Zhou Jiaxi,Feng Sizhou
Abstract
Abstract
Objective
To evaluate the efficacy of autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with favorable-risk acute myeloid leukemia in first remission.
Method
Twenty patients who received auto-HSCT at our center between January 2014 and January 2021 were retrospectively reviewed.
Results
Until last follow-up, three patients in the cohort were dead due to relapse. The estimated 1-year and 5-year overall survival were 95.00% ± 4.87% and 83.82% ± 8.58%, respectively. The estimated 5-year RFS and CIR (cumulative incidence of relapse) were 85.00% ± 7.98% and 15.00% ±7.98%, respectively.
Conclusion
The outcome of auto-HSCT in patients with favorable-risk acute myeloid leukemia in first remission was excellent and auto-HSCT could be an effective treatment for these patients.
Funder
the CAMS Innovation Fund for Medical Sciences
Haihe Laboratory of Cell Ecosystem Innovation Fund
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology